Defensins released by neutrophils are able to kill a broad spectrum of microbes. They also induce leukocyte migration in vitro and elicit inflammatory leukocyte responses at s.c. injection sites in mice. In vitro experiments showed that human defensins enhanced concanavalin A-stimulated murine spleen cell proliferation and IFN-γ production. This led us to examine the effects of human defensins on specific immune responses in vivo. BALB/c mice were immunized with 50 µg of keyhole limpet hemocyanin (KLH) adsorbed to aluminum hydroxide and administered with defensins in aqueous solution. Intraperitoneal administration of defensins significantly increased the production of KLH-specific IgG1, IgG2a and IgG2b antibodies 14 days after immunization. In vitro splenic KLH-specific proliferative responses were higher in mice treated with KLH and defensins than in those treated with KLH alone. Increased IFN-γ and, to a lesser extent, IL-4 production were also detected in the supernatants of ex vivo KLH-activated spleen cells from mice treated with defensins. Finally, defensins significantly enhanced the antibody response to a syngeneic tumor antigen, lymphoma Ig idiotype and also augmented resistance to tumor challenge. These results indicate that defensins act as potent immune adjuvants by inducing the production of lymphokines, which promote T cell-dependent cellular immunity and antigen-specific Ig production. Thus, defensins appear to function as neutrophil-derived signals that promote adaptive immune responses.
Introduction
Neutrophils have been recognized as the first line of stored in the cytoplasmic granules of neutrophils, some macrophages and intestinal Paneth cells (4,5). In human host defense in infections. In the course of inflammation, neutrophils utilize oxygen-dependent and -independent neutrophils, defensins comprise 30-50% of the granule proteins (6,7). Defensins have the ability to kill a broad spectrum mechanisms to kill ingested microbes, the latter pathway involving the discharge of antibiotic proteins and proteases of microbes including Gram-negative and -positive bacteria, fungi, and selected enveloped viruses. In addition to their present in neutrophil granules into phagosomes (1,2). Neutrophils also produce and release into the extracellular milieu antimicrobial activity, defensins have been reported to induce human monocyte migration in vitro (8). Recently we showed several antimicrobial proteins including defensins and CAP37/ azurocidin by the process of degranulation (3). Defensins that both human defensins and CAP37/azurocidin purified from neutrophil granules are chemoattractants for resting constitute a family of cationic antimicrobial proteins that are human T cells in vitro and in vivo in mice (9). This suggests Immunization that defensins may play a role in the communication between
Mice were immunized i.p. once on day 0 with 50 µg of KLH cell types involved in innate or natural resistance such as adsorbed to aluminum hydroxide dissolved in 0.2 ml of neutrophils, and those responsible for adaptive immunity such PBS containing 0.1% normal mouse serum. Some mice also as T and B cells. To analyze this further we examined received i.p. either 0.01 to 1 µg of human defensins or murine whether and how well defensins could act as adjuvants with IL-12 dissolved in 0.2 ml of PBS containing 0.1% normal immunoenhancing effects. mouse serum. Control mice were injected i.p. with PBS Experiments were performed by immunizing BALB/c mice containing 0.1% normal mouse serum. Fourteen days after with keyhole limpet hemocyanin (KLH) adsorbed to aluminum KLH injection, mice were sacrificed, and sera and spleens hydroxide with or without injections of defensins. Immunization were obtained. All experiments were performed with three with protein adsorbed to aluminum hydroxide induces T cellmice per group and were performed 3-4 times with a represdependent immune responses and favors a T h 2-mediated entative experiment being shown. Mice were immunized i.p. humoral immunity. Such an approach has been used to with 50 µg 38C13-Id-KLH or control IgM-KLH in PBS in a examine antigen-specific cellular and humoral responses volume of 0.2 ml as indicated, with or without defensins. and adjuvant activity (10-13). IL-12 is known to induce Measurement of KLH-specific antibodies differentiation of T h 1 cells and the development of cellmediated immune response (14, 15) . Since IL-12 was shown Serum levels of KLH-specific antibodies were measured by to be a potent adjuvant primarily by inducing synthesis of ELISA (17) . Briefly, 96-well flat-bottom plates were coated T h 1-related Ig production (11), we used IL-12 as a control in with 10 µg/ml of KLH in carbonate buffer (0.1 M NaHCO 3 , this study. pH 9.6) for 2 h and washed 3 times with PBS containing 0.05% Triton X-100. This washing buffer was used for washing at all steps. The plates then were incubated with a blocking buffer Methods (5% dry milk in PBS) for 1 h to saturate non-specific binding sites. Serial 5-fold dilutions of the sera in PBS ϩ 2% BSA Reagents (Sigma) were added for 1 h followed by a 30 min incubation with isotype-specific biotinylated anti-mouse antisera (The KLH was obtained from Calbiochem (La Jolla, CA). LipopolyBinding Site, San Diego, CA). After washing 5 times, saccharide (LPS; Escherichia coli; 055:B5) and concanavalin streptavidin-peroxidase (The Binding Site) in PBS ϩ 2% BSA A (Con A) were purchased from Sigma (St Louis, MO). Murine was added for 30 min. The plates then were washed 7 times, IL-12 (sp. act. 4.6ϫ10 6 U/mg) was supplied by Genetics the substrate ABTS (Kirkegaard & Perry, Gaithersburg, MD) Institute (Cambridge, MA). Defensins were purified to homowas added and the absorbance was determined at 405 nm geneity from granules of neutrophils obtained from normal with a reference wavelength of 490 nm. donors as reported previously (9). Amino acid sequence analysis of the preparation revealed the presence of three Determination of phenotype of peritoneal cell population related sequences; human neutrophil peptide (HNP)-1 which Peritoneal cells of mice immunized with 50 µg of KLH (on has Ala as the N-terminal residue (50%), HNP-3 which has day 0) and injected with 1 µg of defensins for five consecutive Asp as the N-terminal residue (20%), and HNP-2 which is days were collected on day 14, and cell phenotyping was shorter than HNP-1 and HNP-3 by one N-terminal residue performed by using anti-mouse antibodies to B220, CD3, (30%). No other sequences were detected. The results of CD4 and CD8. Cells were analyzed with a FACScan flow amino acid analysis corresponded well with amino acid cytometer to determine the percentage of positive cells. composition of defensins suggesting that the preparation contained Ͼ95% defensins. Moreover, no protein contaminAssays of lymphokine production and proliferation ants were detected by matrix-assisted laser desorbtion/ Single cells prepared from spleens obtained from immunized ionization and time-of-flight (MALDI-TOF) mass spectroscopy.
mice were cultured in 24-well plates at a density of Endotoxin level in purified defensins was Ͻ0.1 endotoxin unit/ 2ϫ10 6 /ml in RPMI 1640 supplemented with 10% FBS, 4 mM 20 µg of protein as measured by chromogenic Limulus glutamine, 19 mM HEPES, 100 U/ml penicillin and 100 µg/ml amebocyte lysate assays. In some experiments the activity streptomycin at 37°C in 5% CO 2 . KLH at 50 µg/ml was added of defensin preparation was compared with a preparation of to the cultures. The supernatants were harvested after 48 h, synthetic defensin (HNP-1) from American Peptide Company and tested for concentrations of IFN-γ and IL-4 by specific (Sunnyvale, CA).
ELISA kits (IFN-γ; Genzyme, Cambridge, MA/IL-4; Endogen, Idiotypic IgM (38C13-Id) was rescued by somatic cell Boston, MA). Sensitivity limits of IFN-γ and IL-4 were 27.0 and hybridization as described previously (16) , and 38C13-Id and 5.8 pg/ml respectively. Triplicate cultures of 5ϫ10 5 spleen a control IgM(k) were purified from ascites and coupled to cells/well were incubated with KLH or medium alone in a final KLH using 0.1% glutaraldehyde. volume of 0.1 ml RPMI 1640 supplemented with 10% FBS, 4 mM glutamine, 19 mM HEPES, 100 U/ml penicillin and Animals 100 µg/ml streptomycin in 96-well microculture plates at 37°C Female BALB/c and C3H/HeN MTV -mice were obtained in 5% CO 2 . After 5 days, cell proliferation was measured from the Animal Production Area (National Cancer Instituteby colorimetric assay using MTT (Sigma) according to the Frederick Cancer Research and Development Center, standard method (18) . To determine whether defensins activate normal murine Frederick, MD), and were used at 8-12 weeks of age. To determine whether human defensins could activate murine doses of defensins in 96-well microculture plates at 37°C in immune cells, we examined the in vitro effect of defensins on 5% CO 2 . After 3 days, the cell proliferation was measured by the proliferation and lymphokine production by murine normal MTT assay. Spleen cells prepared from untreated mice were spleen cells. Defensins were not mitogenic by themselves, incubated with Con A along with various doses of defensins but they enhanced the proliferation of Con A-stimulated murine in 24-well plates at a density of 2ϫ10 6 /ml of RPMI 1640 spleen cells in a dose-dependent manner. Defensins did supplemented with 10% FBS at 37°C in 5% CO 2 . After 48 h, not increase proliferation of LPS-stimulated cells (Fig. 1A) . culture supernatants were harvested and assayed for IFN-γ
Defensins also enhanced IFN-γ production by Con A-stimuby ELISA.
lated murine spleen cells (Fig. 1B) . These results suggest that human defensins can co-stimulate normal murine T cells.
Cell staining and flow cytometric analysis Defensins up-regulate anti-KLH IgG1, IgG2a and IgG2b antiSingle cells from spleens and peritoneal cells obtained from
body responses in vivo immunized mice were counted and adjusted to 1ϫ10 6 /ml. The cells then were incubated with the appropriate directly Previously reported data revealed that mouse serum anti-KLH labeled antibodies. The antibodies used were: goat antiantibody levels usually are maximal from 7 days to at least 5 mouse IgM from Fisher Scientific (Pittsburgh, PA), B220 (6B2;
weeks after injection of a single dose of KLH adsorbed to directed against a murine B cell marker) from PharMingen aluminum hydroxide (10). We therefore chose to assay the (San Diego, CA), CD4 (L3T4; PharMingen) and CD8 (Lyϩ2;
antibody response 14 days after KLH injection and determined PharMingen). After incubation the cells were washed and KLH-specific Ig subclasses by ELISA (Fig. 2 ). Mice injected then fixed with 1% paraformaldehyde, and the cells were once with KLH alone exhibited relatively high serum levels of analyzed using an Epics flow cytometer (Coulter, Hialeah, FL).
IgG1 antibody and low levels of IgG2a and IgG2b. Administration of 1 µg of defensins i.p. daily from day -1 to day 5 Measurement of serum anti-idiotypic antibody significantly (P Ͻ 0.05) augmented the level of KLH-specific As described previously (19) , mouse serum was serially IgG1, IgG2a and IgG2b antibodies in the serum at day 14. diluted over microtiter plates coated with affinity-purified
We also examined the effects of the number of daily defensin 38C13-Id. Binding of antibodies in the serum to 38C13-Id injections on the production of specific antibodies. As shown was detected by horseradish peroxidase-conjugated goat in Fig. 3 , a significant (P Ͻ 0.05) up-regulation of production anti-mouse IgG antibodies. Serum anti-idiotypic antibody of KLH-specific IgG2a and IgG2b antibodies by defensins levels were determined by comparing sera titration curves was observed in mice injected with defensins for at least 3 with a standard curve obtained with a known concentration days. Thus, defensins can act as adjuvants that promote of a mixture of purified monoclonal anti-idiotypic antibodies.
humoral immune responses in vivo. In addition, we compared Antibody levels are expressed in µg/ml serum for individual the ability of purified defensins and a preparation of synthetic mice. In each ELISA, sera obtained from mice immunized defensin (HNP-1) to enhance anti-KLH IgG response. The with control IgM-KLH were included as negative controls.
preparations of natural and synthetic defensins both Such sera never showed any titratable binding activity on significantly augmented the production of anti-KLH IgG (in 38C13-Id.
comparison with PBS) (Fig. 4) . There was no difference in stimulatory activity between 'natural' and synthetic defensin.
Tumor model
These data show the synthetic defensin to have biological The carcinogen-induced 38C13 B cell lymphoma has been activity and argue against a role for contaminants in the previously described (20) . The 38C13 tumor secretes and purified defensin preparation. expresses IgM(k) on the cell surface. Inoculation with as few
Comparison of the immunoenhancing effects of defensins as 10 2 tumor cells i.p. into normal syngeneic C3H/HeJ mice and IL-12 results in uniformly progressive tumor growth and death of the host. Tumor cells from a common frozen stock were It is well established that IL-12 promotes the development passaged in vitro for 3 days before use.
and activation of T h 1 cells (14, 15) , resulting in the production of high levels of IgG2a and IgG2b antibody subclasses (10-Statistical analysis 12). Figure 5 shows the effects of various doses of defensins or IL-12 on the production of KLH-specific Ig subclasses. The The statistical significance of the experimental differences between test and control groups was determined by Student's administration of defensins enhanced the synthesis of KLHspecific IgG1, IgG2a and IgG2b antibodies in a dose-dependt-test or Mann-Whitney test as indicated. Significance was defined at the P Ͻ 0.05 level. For tumor challenge experiments ent manner. In contrast to defensins, IL-12 markedly inhibited KLH-specific IgG1 antibody production. On the other hand, mice were checked daily to determine the date of death. Statistical comparisons of survival curves were performed IL-12 injection up-regulated the synthesis of KLH-specific IgG2a antibody to a significantly (P Ͻ 0.05) greater extent using BMDP IL software (BMDP Statistical Software, Los Angeles, CA) to generate non-parametric Mantel-Cox logthan in mice treated with defensins. IL-12 and defensin administration enhanced KLH-specific IgG2b antibody prorank P values. Mice surviving Ͼ90 days after tumor challenge were euthanized and were reported as long-term survivors.
duction to a similar extent. The pattern of antigen-specific Ig production induced by IL-12 was identical to those previously There was a dose-dependent increase in the proliferation of reported for this selective activator of T h 1 cells (11,12).
spleen cells from mice treated with 0.01-1 µg of defensins Defensins, by contrast, enhanced Ig subclasses that are along with KLH when compared with those treated with presumed to be augmented by both T h 1 and T h 2 cytokines.
KLH alone. Administration of both IL-12 and defensin together had
The effects of defensins on splenic and peritoneal cell subpopadditive immunoenhancing effects (data not shown).
ulations Cytokine production by spleen cells
In order to determine the effect of defensins on various Cytokines released by activated T cells promote the developsubsets of immune cells, spleen cells were stained with mAb ment of antibody responses. We therefore examined the specific for IgM, B220, CD4 and CD8. There was no increase influence of defensins on cytokine production by ex vivo KLHover controls in the total number of spleen cells of mice activated spleen cells from immunized mice. As shown in treated with KLH alone or KLH plus defensins by day 14 Table 1 , relatively low levels of IFN-γ were produced by spleen (Table 2) . Treatments with KLH plus 0.1 or 1 µg of defensins cells of mice treated with PBS or KLH alone. By contrast, resulted in increased numbers of IgM ϩ and B220 ϩ cells there was~3-fold up-regulation of IFN-γ production by spleen (P Ͻ 0.05). The number of CD4 and CD8 T cells was cells from mice treated with 0.1 and 1 µg of defensins when significantly (P Ͻ 0.05) lower in spleens from mice treated compared with the response of mice treated with KLH alone.
with KLH and 1 µg of defensins than in spleens treated with Spleen cells from mice treated with KLH alone produced KLH alone (data not shown). Figure 7 shows a representative significantly (P Ͻ 0.05) higher levels of IL-4 when compared result in which a higher percentage of B220 ϩ /surface IgM ϩ with the value of non-immunized mice. The IL-4 synthesis was cells was observed in the spleen from mice treated with KLH further increased by spleen cells from mice treated with a and 1 µg of defensins when compared with mice treated with low dose (10 ng) of defensins (P Ͻ 0.05). However, spleen KLH alone. Consequently administration of defensins along cells from mice treated with the highest dose (1 µg) of with KLH increased both the splenic B cell populations and defensins had a decreased capacity to produce IL-4 (P Ͻ anti-KLH antibody levels. FACScan analysis of peritoneal cells 0.05). Based on reports that in mice IFN-γ and IL-4 favor the of mice immunized with KLH also demonstrated a significant induction of IgG2a and IgG1 respectively (21-23), our results increase in mature (B220) positive B lymphocytes in mice indicate that defensins enhanced the ability of spleen cells injected with 1 µg of defensin at 14 days. Moreover, synthetic to produce antigen-specific IFN-γ, a T h 1-type cytokine, while defensin induced a significant increase of B220 ϩ cells, the effect of defensins on the production of antigen-specific although at lesser extent than defensin purified from neutro-IL-4, a T h 2 cytokine, varied depending on concentrations phils (Table 3) . administered.
Defensins enhance antibody responses to a syngeneic tumor Effect of defensins on proliferation of spleen cells in response antigen and tumor idiotype-specific resistance to KLH
To evaluate the potency of defensins, we tested the ability KLH-specific in vitro proliferation of spleen cells from immunized mice was determined by colorimetric MTT assays (Fig. 6) .
of defensins to enhance the antibody response to a less Fig. 2 . Serum KLH-specific IgG1, IgG2a and IgG2b antibodies of mice treated with neutrophil defensins or PBS (control). Mice were immunized i.p. with 50 µg of KLH on day 0. 1 µg of defensins was injected i.p. for 7 days from day -1 to day 5. On day 14, KLH-specific antibodies in sera were assayed by ELISA. Data show means and SD of values for three mice. Statistically significant differences * P Ͻ 0.01 and ** P Ͻ 0.05 relative to control mice.
immunogenic syngeneic tumor antigen. The unique amino significantly (P Ͻ 0.05) enhanced by the addition of defensins at doses of 0.1 and 1 µg (mean 349 Ϯ 156 and 270 Ϯ acid sequences comprising the variable regions of Ig receptor heavy and light chains on clonal B cell malignancies can 114 µg/ml respectively). The specificity of the induced antibodies for 38C13 idiotype was demonstrated by the lack of serve as antigenic determinants (idiotypes) and thus as tumorspecific antigens (24, 25) . In the 38C13 lymphoma model, binding of these sera to a control IgM protein (data not shown). Ten mice per group were also challenged i.p. with syngeneic Ig isolated from this tumor is completely nonimmunogenic. However, immunization with Id conjugated to viable 38C13 lymphoma cells from a single preparation obtained at time zero. A tumor dose as low as 100 cells is lethal KLH (Id-KLH) elicits idiotype-specific antibodies and this humoral response is sufficient to mediate resistance to in 100% of control immunized mice. A single immunization with Id-KLH produces resistance against subsequent challenge lymphoma challenge (26) . Mice were given a single immunization with Id-KLH i.p., with or without doses of defensins, with this minimum lethal dose and previous studies have established the magnitude of the challenge dose (20) . Thereranging from 0.01 to 1 µg/day, administered concurrently for 7 days (day -1 to day 5). Control animals received a single fore, in this experiment a dose of 10 4 tumor cells, 100 times the minimum lethal dose, was used to allow detection of immunization with a control IgM-KLH alone. In the experiment shown in Fig. 8 , serum samples were collected from four to improvements in survival afforded by the addition of defensins. Compared with Id-KLH alone, significantly prolonged survival five randomly selected individual mice per group 2 weeks after immunization. Baseline antibody levels elicited by Idwas observed for mice which received defensins at the 1 µg dose (Table 4 , group 1; range 18-Ͼ90 versus 18-19 days). KLH immunization alone (24 Ϯ 5.4 µg/ml; mean Ϯ SEM) were IgG1 production. Mice were immunized with 50 µg of KLH (on day 0), injected i.p. with PBS, neutrophil defensins (1 µg ) or synthetic of KLH on day 0. Defensins (1 µg)was injected i.p. for 1 day (day 0), 3 days (day -1 to 1), 5 days (day -1 to 3) or 7 days (day -1 to 5).
defensin (HNP-1, 1 µg) daily for 5 consecutive days. On day 14, KLH-specific IgG in sera were assayed by ELISA. Scatter graph Control mice were injected with PBS alone. On day 14, KLH-specific antibodies in sera were assayed by ELISA. Data show means and shows data for 10 mice in each group. Data were analyzed by MannWhitney test, the two-tailed P value was determined (Ͻ0.015 for SD of values for three mice. Statistically significant differences * P Ͻ 0.05 and ** P Ͻ 0.01 relative to mice treated with KLH alone. synthetic defensin and Ͻ0.003 for purified defensins compared to mice injected with PBS). 
a Spleen cells were prepared from mice with PBS or KLH along a Spleen cells prepared from mice were incubated in vitro in 24-well with various doses of defensins or PBS on day 14 after KLH treatment. plates at a density of 2ϫ10 6 /ml in RPMI 1640 supplemented with Splenic IgM ϩ cells and B220 ϩ cells were evaluated by flow cytometric 10% FBS at 37°C in 5% CO 2 . The cultures were incubated with 50 analysis as described in Materials and Methods. µg/ml of KLH. After 48 h, cultures supernatants were harvested, and b Data show means Ϯ SD for three mice. assayed for IFN-γ and IL-4 content by ELISA.
c Significantly different from the value of mice treated with KLH b Data show means Ϯ SD for three mice. IFN-γ and IL-4 levels are alone (P Ͻ 0.05). expressed as pg/ml. c Significantly different from the value of mice treated with KLH alone (P Ͻ 0.05).
d Significantly different from the value of mice treated with PBS alone (P Ͻ 0.05) suggested that neutrophils could release chemoattractants Furthermore, one long-term, tumor-free survivor was observed that mediate T cell accumulation at sites of inflammation, and in this defensin-treated group. The small increase in survival led to the biochemical identification of defensins and CAP37/ among mice receiving lower doses of defensins with Id-KLH, azurocidin released by degranulation from IL-8-stimulated compared with Id-KLH alone, was not statistically significant.
neutrophils as the T cell chemoattractants (9). Moreover, it has been reported that depleting rat neutrophils by treatment Discussion with anti-neutrophil antiserum (28, 29) or suppression of neutrophil activities by infusion of anti-IL-8 mAb reduced Taub et al. showed that human neutrophils stimulated in vitro with IL-8 released a granule-derived factor(s) that induces subsequent delayed-type hypersensitivity responses (30) . These results suggest that neutrophil-derived peptides may in vitro human T cell and monocyte chemotaxis (27) . This play an important pathophysiological role in promoting T celldependent immune responses by activation of T cells. Our results demonstrate that neutrophil-derived defensins have potent immunoadjuvant activity promoting antigen-specific Ig responses and tumor immunity. This is reinforced by data showing that intranasal administration of human defensins to mice enhances the systemic antibody responses to coadministered ovalbumin (31).
IL-12, induced in the course of innate host response, is reported to act as an adjuvant by promoting specific cellmediated immunity reactions (13, (32) (33) (34) (35) . IL-12 is a known inducer of T h 1 development but an inhibitor of T h 2 differentiation as evidenced by increased T h 1-type antibodies (IgG2a/ IgG2b) and decreased T h 2-type antibody (IgG1) (10-12). In this study we confirmed that IL-12 up-regulated KLH-specific IgG2a and IgG2b antibody subclasses, but down-regulated KLH-specific IgG1 subclass. In contrast, human defensins increased the production of KLH-specific murine IgG1, as well as IgG2a and IgG2b subclasses in vivo. The pattern of synthesis of Ig subclasses stimulated by defensins suggests that defensins up-regulate antigen-specific Ig synthesis medi- to the increase in B cell number, the ability of B cells to produce particular Ig subclasses is also dependent on cytokines produced by CD4 ϩ T cells (10,32,36-38). IFN-γ and IL-4 play pivotal roles in regulating Ig isotype switching 
LPS lipopolysaccharide
The tissue distribution of α-defensins is species dependent. They have been isolated from human, rabbit, guinea pig and References rat neutrophils, but murine neutrophils lack detectable α-
